Clinical Trial Update: Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

View source ↗

Summary

Clinical trial update shows ongoing recruitment for assessing the safety of elacestrant in ER-positive, HER2-negative metastatic breast cancer with ESR1 mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: ESR1 Gene Mutation, Advanced Breast Cancer | Status: RECRUITING